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An Improved Model of the Trypanosoma brucei CTP
Synthetase Glutaminase Domain–Acivicin Complex
Juliana Oliveira de Souza, Alice Dawson, and William N. Hunter*[a]
The natural product acivicin inhibits the glutaminase activity of
cytidine triphosphate (CTP) synthetase and is a potent lead
compound for drug discovery in the area of neglected tropical
diseases, specifically trypanosomaisis. A 2.1-a-resolution crystal
structure of the acivicin adduct with the glutaminase domain
from Trypanosoma brucei CTP synthetase has been deposited
in the RCSB Protein Data Bank (PDB) and provides a template
for structure-based approaches to design new inhibitors. How-
ever, our assessment of that data identified deficiencies in the
model. We now report an improved and corrected inhibitor
structure with changes to the chirality at one position, the ori-
entation and covalent structure of the isoxazoline moiety, and
the location of a chloride ion in an oxyanion binding site that
is exploited during catalysis. The model is now in agreement
with established chemical principles and allows an accurate
description of molecular recognition of the ligand and the
mode of binding in a potentially valuable drug target.
CTP synthetase [EC: 6.3.4.2] catalyzes the formation of CTP
from UTP by coupling dephosphorylation of ATP with deami-
nation of glutamine to glutamate, the latter to supply the re-
quired amino group. The enzyme, which consists of distinct
synthetase and glutaminase domains, is rate limiting in the
synthesis of cytosine nucleotides required to maintain RNA
and DNA levels. Given such a critical role in metabolism CTP
synthetase represents a potential target for therapeutic inter-
vention in a range of diseases.[1, 2] This extends to trypanoso-
miasis, or African sleeping sickness, a potentially fatal infection
with the protozoan parasite Trypanosoma brucei. This parasite
possesses a low level of CTP and moreover is unable to salvage
cytosine from the human host, suggesting the enzyme as a fa-
vorable point of intervention.[2–4] We assessed the potential of
this target for early stage drug discovery in trypanosomaisis. A
major consideration is whether such a target is enabled with
access to structural information.[5] In this case, the Structural
Genomics Consortium (SGC, www.thesgc.org) had determined
the structure of the T. brucei glutaminase domain in complex
with acivicin, deposited coordinates and structure factors in
the RCSB Protein Data Bank (PDB) in 2008 (PDB ID: 2W7T). Aci-
vicin (Figure 1), a fermentation product of Streptomyces sviceus,
inhibits enzymes like CTP synthetase that catalyze amido trans-
fers from l-glutamine. This natural product displays potent an-
ticancer activities, however, it has not progressed beyond
phase 1 clinical trials due to neurotoxicity.[6] Nevertheless, the
compound displays antitrypanosomatid activity and as such
the structure of a CTP synthetase complex with a lead com-
pound is potentially valuable. Indeed, the SGC model has been
used for docking calculations which formed the basis for stud-
ies reported in ChemMedChem where researchers sought to
design acivicin analogues as more potent T. brucei CTP synthe-
tase inhibitors.[7]
However, our inspection of the available data and the SGC
model revealed several issues. The details in the drug binding
site were inconsistent with the structure of acivicin (Figure 1)
in terms of the chiral center at C5, the hybridization at C3,
some covalent bond lengths and the hydrogen bonding ca-
pacity of the ligand was not optimized. Moreover, difference
Fourier syntheses, electron and difference density including
omit maps suggested the orientation of the isoxazoline ring
was incorrect (Supporting Information Figures S1–S3). We ex-
tended the crystallographic refinement seeking to address
these deficiencies and now present a model consistent with
established chemical principles.
Coordinates and structure factor data for PDB ID: 2W7T
were inspected and compared with those output from PDB-
REDO, an automated refinement process designed to improve
crystallographic models.[8] In common with our experience,[9]
the PDB-REDO model was identified as being significantly im-
proved, and provided the starting point for further refinement.
The inspection of electron and difference density maps and
model manipulation were carried out using COOT[10] with least-
squares calculations performed in REFMAC5.[11] Water mole-
cules, three chloride ions and several side chain conformers
were included in the model. The dictionary of ligand restraints
was assembled using Grade.[12] Geometry was assessed with
Figure 1. The structure and numbering scheme of acivicin, (2S)-amino[(5S)-3-
chloro-4,5-dihydro-1,2-oxazol-5-yl]ethanoic acid.
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MolProbity[13] and the PDB Validate Tools. Figures were gener-
ated with PyMOL (Schrçdinger). Coordinates have been depos-
ited with the PDB (PDB ID: 5N29).
The glutaminase domain of T. brucei CTP synthetase, (resi-
dues 319–589), following incubation with acivicin, crystallized
in space group P212121 with one molecule in the asymmetric
unit and diffracted to 2.1 a resolution. Three refined models
are available, the original PDB entry (PDB ID: 2W7T), the PDB-
REDO version and from this current study, with crystallographic
statistics collated and compared as Supporting Information
Table S1. Our continued refinement produced a model with ac-
ceptable geometric parameters and agreement with the dif-
fraction data. This model is essentially the same as from PDB-
REDO with the major difference that the ligand now has cor-
rect stereochemistry. This means that the features in the active
site relevant to activation, specificity and interactions with the
inhibitor can now be accurately described. Of note also is the
identification of a chloride ion bound in the active site close to
the acivicin adduct. A water molecule with a low isotropic ther-
mal parameter (B-factor ~5 a2), significantly less than the sur-
rounding residues previously occupied this position. Compar-
ing peak heights in difference density omit maps of S and car-
bonyl O atoms with this site suggested that it was occupied
by some species with more electrons than O, slightly less than
S. The site interacts with three amide groups accepting hydro-
gen bonds of length 3.1–3.2 a (Gln423, Arg500, Tyr501),
a water molecule (3.9 a) and 3.6 a distant from acivicin C4. We
therefore included chloride at this position (see below, B-factor
24.3 a2), the ion likely derived from the crystallization and
cryo-protectant conditions, which included 300 mm NaCl. We
refined the ion at full occupancy but recognize the possibility
that it is a mixed water/ion site. The density maps at Phe393
do not match to the size and shape of that side chain being
more suggestive of a methionine or leucine. Without recourse
to sequence information on the expression system we left this
as a phenylalanine, which is consistent with genomic data.
The glutaminase domain is dominated by a core b-sheet of
seven strands decorated on one side by six a-helices, on the
other by four helices and two parallel b-strands (Figure 2). The
active site is located at one end of the sheet in a small, or-
dered, polar cavity. One side of this cavity is lined by two poly-
peptide segments extending from the pair of strands, the
other by a C-terminal extension to a b-strand that is part of
the core sheet. The width of the cavity is about 8 a as mea-
sured from Gly391 N to Arg498 O, this is a vector that bisects
the space between the ligand C1 and Cys419 S atoms.
The corrected orientation of the ligand now results in four
out of five functional groups participating in hydrogen bond-
ing interactions directly with the enzyme, the fifth to a water
molecule that is then in contact with the enzyme (Figure 3).
N2 and O3 accept hydrogen bonds donated by the main chain
amides of Leu420 and Gly392 respectively. The C1 carboxylate
interacts with solvent, and the side chains of basic residues
Arg498 and His549. The proximity of the Arg498 carbonyl
group (3.0 a) suggests that the carboxylate is protonated. The
amino substituent on C2 donates hydrogen bonds to water
and the carbonyl of Gly392.
Although the fit of the isoxazoline moiety to the electron
density is supportive of sp2 hybridization at C3, at 2.1 a resolu-
tion the data are insufficient to provide certainty in this re-
spect. However, inspection of the electron density associated
Figure 2. Secondary structure, fold, and acivicin binding site in the glutami-
nase domain of T. brucei CTP synthetase. Helices are shown as cyan cylin-
ders, b-strands as purple arrows, and the polypeptide in extended conforma-
tion as a brown coil. The covalent modification following reaction with acivi-
cin is depicted as van der Waals spheres (C: yellow, N: blue, O: red, S:
orange). The positions of the N- and C-terminal residues of the domain are
labeled.
Figure 3. Binding mode of the acivicin–glutaminase domain adduct. The
enzyme surface is depicted as a semi-transparent van der Waals surface,
with key residues shown as sticks using the color scheme in Figure 2, except
protein C atoms are colored gray. Potential hydrogen bonds are depicted as
dashed lines. The hydrogen bonding interactions involving the acivicin
adduct all fall in the range 3.0–3.2 a. The four dashed lines colored green
identify interactions with the chloride ion (green sphere). These are in the
range of 3.0–3.2 a for interactions with amide nitrogen atoms, and we note
the potential for a C4-H···Cl@ association, distance 3.6 a. The S stereochemis-
try positions are labeled. For the purpose of clarity, water molecules are not
shown.
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with the high resolution 1.5 a structure of Helicobacter pylori g-
glutamyltranspeptidase is unambiguous in the assignment of
an sp2 C3.[14,15] This would be consistent with our refined
model and supports a straightforward mechanism of reaction
whereby acivicin undergoes nucleophilic attack from Cys419,
leading to the formation of a tetrahedral oxyanion with sp3-hy-
bridized C3, then a collapse of this intermediate with release
of chloride and restoration of the starting point sp2 C3 and co-
valent linkage to Cys419. The assignment of a C3=N2 double
bond is further supported by the hydrogen bonding interac-
tion whereby the Leu420 amide donates to the acceptor N2.
We note also that an sp2-hybridized C3 is assigned in the high-
resolution structure of Bacillus subtilis g-glutamyltranspepti-
dase.[16] In stark contrast an sp3-hybridized C3 is reported in
the structure of the Escherichia coli g-glutamyltranspeptidase
acivicin adduct.[17] However, in this case the difference Fourier
synthesis based on PDB ID: 2Z8K for this structure (not shown)
presents significant positive and negative features that suggest
deficiencies in the model. Moreover, the authors invoke
a highly complicated mechanism that involves acivicin ring
opening followed by ring closure to leave an anionic N2
group. We judge that this is unlikely and that established
chemical principles explain the formation of the covalent
adduct with sp2-hybridized C3 as noted above.
The activation of the nucleophilic Cys419 is supported by
the position of His549, 3.6 a distant, which in turn is posi-
tioned by a hydrogen bond with the side chain of Glu551. Al-
though His499 is nearby and an alternative rotamer could posi-
tion the basic side chain close to the cysteine thiol, we note
that a hydrogen bond with Glu502 (not shown) helps to select
for the observed rotamer holding the basic side chain away
from the active site. Stabilization of the oxyanion intermediate
formed during the reaction with acivicin, or during catalysis
may benefit from the position of the amine and amide groups
of Gln423, Arg500 and Tyr501 respectively forming a positively
charged environment similar to that observed near the cys-
teine protease-like catalytic triad in trypanothione synthetase-
amidase.[18] This site is where chloride binds.
The PDB is a hugely valuable resource for biochemical and
medicinal chemistry research but unfortunately, serious errors
in ligand–protein complexes are not uncommon.[8] For our
own part, we previously identified the incorrect structure of
the potent antifolate and anticancer agent assigned as
LY374571,[19] and showed that structures of the fatty acid bind-
ing site of the human peroxisome proliferator-activated recep-
tors-b/d are not occupied by lipid-lowering synthetic agents
but rather by endogenous ligands derived from the bacterial
expression system.[20] In respect of the glutaminase domain of
CTP synthetase from T. brucei, then our inspection identified
deficiencies in the crystallographic model. These have been
corrected and future efforts to obtain novel lead compounds
might progress with an accurate template of the binding site
occupied by an inhibitor and an anion now available.
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